Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel G Haller

Showing results (111-120 of 112) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 112 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2022
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant TrialsClaire Gallois, Qian Shi, Jeffrey P Meyers, et al.
The Oncologist|December 20, 2019
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204)A Bapsi Chakravarthy, Fengmin Zhao, Neal J Meropol, et al.
Pageof 12

Showing results (111-120 of 112) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 112 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2022
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant TrialsClaire Gallois, Qian Shi, Jeffrey P Meyers, et al.
The Oncologist|December 20, 2019
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204)A Bapsi Chakravarthy, Fengmin Zhao, Neal J Meropol, et al.
Pageof 12